TSE:EXE Extendicare (EXE) Stock Price, News & Analysis C$10.14 +0.13 (+1.30%) (As of 11/15/2024 08:56 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlines About Extendicare Stock (TSE:EXE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Extendicare alerts:Sign Up Key Stats Today's RangeC$9.99▼C$10.2050-Day RangeC$8.66▼C$10.1852-Week RangeC$6.41▼C$10.43Volume155,352 shsAverage Volume134,798 shsMarket CapitalizationC$846.39 millionP/E Ratio14.91Dividend Yield4.73%Price TargetC$9.50Consensus RatingHold Company OverviewExtendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties. It operates through the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada.Read More… Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Extendicare Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks24th Percentile Overall ScoreEXE MarketRank™: Extendicare scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingExtendicare has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExtendicare has only been the subject of 1 research reports in the past 90 days.Read more about Extendicare's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Extendicare is 14.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.30.Price to Earnings Ratio vs. SectorThe P/E ratio of Extendicare is 14.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.45.Price to Book Value per Share RatioExtendicare has a P/B Ratio of 7.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Extendicare's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EXE. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipExtendicare is a leading dividend payer. It pays a dividend yield of 5.14%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthExtendicare does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Extendicare is 70.59%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Extendicare's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for EXE. News and Social Media2.7 / 5News Sentiment0.85 News SentimentExtendicare has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Extendicare this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for EXE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Extendicare insiders have not sold or bought any company stock.Percentage Held by Insiders13.92% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.16% of the stock of Extendicare is held by institutions.Read more about Extendicare's insider trading history. Receive EXE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter. Email Address EXE Stock News HeadlinesLeede Financial Predicts Increased Earnings for ExtendicareNovember 17 at 1:33 AM | americanbankingnews.comExtendicare (TSE:EXE) Stock Price Expected to Rise, TD Securities Analyst SaysNovember 16 at 3:51 AM | americanbankingnews.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 18, 2024 | DTI (Ad)Extendicare Inc: Extendicare Announces 2024 Third Quarter Results and Early Redemption of 2025 DebenturesNovember 13, 2024 | finanznachrichten.deExtendicare (EXE) Scheduled to Post Quarterly Earnings on TuesdayNovember 10, 2024 | americanbankingnews.comWhere to Invest $5,000 in OctoberOctober 29, 2024 | msn.comInvest $7,000 in This Dividend Stock for Immense Passive IncomeOctober 19, 2024 | msn.com3 No-Brainer Healthcare Stocks to Buy With $500 Right NowOctober 19, 2024 | msn.comSee More Headlines EXE Stock Analysis - Frequently Asked Questions How have EXE shares performed this year? Extendicare's stock was trading at C$7.28 at the beginning of 2024. Since then, EXE shares have increased by 39.3% and is now trading at C$10.14. View the best growth stocks for 2024 here. How do I buy shares of Extendicare? Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Extendicare own? Based on aggregate information from My MarketBeat watchlists, some other companies that Extendicare investors own include Enbridge (ENB), Enterprise Products Partners (EPD), Algonquin Power & Utilities (AQN), Bank of Nova Scotia (BNS), NVIDIA (NVDA), Pembina Pipeline (PPL) and BCE (BCE). Company Calendar Ex-Dividend for 10/15 Dividend9/27/2024Dividend Payable10/15/2024Ex-Dividend for 11/15 Dividend10/31/2024Dividend Payable11/15/2024Today11/17/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Medical Care Facilities Sub-IndustryN/A Current SymbolTSE:EXE CUSIPN/A CIKN/A Webwww.extendicare.com Phone905-470-4000FaxN/AEmployees23,000Year FoundedN/APrice Target and Rating Average Stock Price TargetC$9.50 High Stock Price TargetC$10.50 Low Stock Price TargetC$8.50 Potential Upside/Downside-6.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.68 Trailing P/E Ratio14.91 Forward P/E Ratio16.53 P/E GrowthN/ANet IncomeC$59.44 million Net Margins4.28% Pretax MarginN/A Return on Equity60.00% Return on Assets7.16% Debt Debt-to-Equity Ratio305.80 Current Ratio0.60 Quick Ratio0.98 Sales & Book Value Annual SalesC$1.39 billion Price / Sales0.61 Cash FlowC$3.17 per share Price / Cash Flow3.20 Book ValueC$1.28 per share Price / Book7.92Miscellaneous Outstanding Shares83,470,000Free FloatN/AMarket CapC$846.39 million OptionableNot Optionable Beta1.26 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (TSE:EXE) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Extendicare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Extendicare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.